KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Total Debt (2016 - 2025)

AbbVie (ABBV) has disclosed Total Debt for 14 consecutive years, with $61.4 billion as the latest value for Q4 2025.

  • On a quarterly basis, Total Debt fell 8.5% to $61.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $61.4 billion, a 8.5% decrease, with the full-year FY2025 number at $61.4 billion, down 8.5% from a year prior.
  • Total Debt was $61.4 billion for Q4 2025 at AbbVie, down from $65.0 billion in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $82.1 billion in Q2 2021 to a low of $55.8 billion in Q2 2023.
  • A 5-year average of $67.1 billion and a median of $65.5 billion in 2025 define the central range for Total Debt.
  • Peak YoY movement for Total Debt: dropped 25.15% in 2022, then increased 26.56% in 2024.
  • AbbVie's Total Debt stood at $64.2 billion in 2021, then dropped by 7.89% to $59.1 billion in 2022, then increased by 0.42% to $59.4 billion in 2023, then increased by 13.07% to $67.1 billion in 2024, then fell by 8.5% to $61.4 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Total Debt are $61.4 billion (Q4 2025), $65.0 billion (Q3 2025), and $65.0 billion (Q2 2025).